Management of Major Depressive Disorder with Insomnia

First-Line Treatment

• The American Academy of Sleep Medicine recommends mirtazapine as a first-line treatment for patients with major depressive disorder and insomnia, while zopiclone should be used only for short-term management if needed 1, 2
• Mirtazapine (7.5-15 mg at bedtime) is an effective option for patients with comorbid depression and insomnia, as it promotes sleep, appetite, and weight gain 3, 2

Role of Zopiclone in Treatment

• The American Academy of Sleep Medicine suggests that short-intermediate acting benzodiazepine receptor agonists like zopiclone should be used only for short-term management and supplemented with behavioral and cognitive therapies when possible 1
• Zopiclone should not be considered first-line for patients with depression and insomnia, as sedating antidepressants are preferred when these conditions coexist 1, 2

Treatment Approach

• The initial treatment for patients with major depressive disorder and insomnia is mirtazapine 7.5-15 mg at bedtime 3, 2
• If immediate relief is needed while waiting for mirtazapine to take effect, zopiclone may be used short-term (≤4 weeks) 1
• Cognitive behavioral therapy, such as CBT-I, should be added to pharmacotherapy whenever possible 1, 2

Monitoring and Adjustment

• Patients should be followed regularly (every few weeks initially) to assess effectiveness, side effects, and need for continued medication 1
• Mirtazapine's dose can be increased if needed, and it is essential to be aware that it may cause daytime sedation, increased appetite, and weight gain in some patients 3, 2

Important Considerations

• Sleep hygiene alone is insufficient for treating chronic insomnia but should be used in combination with pharmacotherapy and behavioral interventions 1, 2
• It is crucial to avoid using zopiclone as a long-term solution and to taper gradually to prevent withdrawal symptoms or rebound insomnia when discontinuing either medication 1